Pain in osteoarthritis
Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain
R.E. Miller1, A.-M. Malfait2, J.A. Block3
- Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago IL, USA.
- Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago IL, USA.
- Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago IL, USA. joel_block@rush.edu
CER10822
2017 Vol.35, N°5 ,Suppl.107
PI 0085, PF 0087
Pain in osteoarthritis
Free to view
(click on article PDF icon to read the article)
PMID: 28967370 [PubMed]
Received: 16/09/2017
Accepted : 16/09/2017
In Press: 28/09/2017
Published: 29/09/2017
Abstract
Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). This narrative review describes the current status of NGF-blockade for the treatment of OA pain. We summarise briefly current evidence for the efficacy and risks of anti-NGF blockade. Two anti-NGF antibodies, tanuzemab and fasinumab, are in active development, with tanuzemab close to completing Phase 3 trials in preparation for an application for approval for clinical use.
